Replies to post #236660 on Avid Bioservices Inc (CDMO)

[biopharm]

Peck must have worked with Berman, who is now with AZN/Medimmune, and AZN is collaborating with PPHM. But Kolltan bought the antibody from Medimmune and GILD is an investor in Kolltan.Wow

Why did Kolltan pull their IPO? do they have a deal and don't have to go public. As a private company there is no reason to disclose right now.

Very interesting!
eastcoastguy

I agree and on top of that, we have ties over to Bruce Chabner via Kolltan (most recent) BOD = Frank Karbe

------------------

Frank Karbe

Mr. Frank L. Karbe served as a Consultant of Exelixis, Inc. from June 2, 2014 to June 2, 2015. Mr. Karbe served as the Chief Financial Officer and Executive Vice President of Exelixis, Inc. from July 9, 2007 to June 2, 2014, and from January 2004 to June 2, 2014 respectively, and served as its Principal Accounting Officer until June 2, 2014. He served as Senior Vice President of Exelixis Inc. since January 2004. From 1997 to January 2004, he served as an Investment Banker for Goldman Sachs & Co., where he served as Vice President in the healthcare group focusing on corporate finance and mergers & acquisitions in the biotechnology industry. Prior to Goldman Sachs, Mr. Karbe served in various positions in the finance department of The Royal Dutch/Shell Group in Europe. He has broad experience in the areas of mergers & acquisitions and corporate finance, and also has a breadth of knowledge in the biotechnology and pharmaceutical industries. He has been an Independent Director of Tekmira Pharmaceuticals Corporation since January 28, 2010. He has been a Director of Kolltan Pharmaceuticals, Inc. since April 2015. Mr. Karbe holds a Diplom Kaufmann from the WHU--Otto Beisheim Graduate School of Management, Koblenz, Germany (equivalent to a U.S. Masters of Business Administration).

http://www.bloomberg.com/research/stocks/people/person.asp?personId=8573684&ticker=EXEL

--------------------------------------------------

I don't like Exelixis, could be coincidence in a way but a look at their collaboration page:

Bristol Myers Squibb = all the BMS ties to sabotage of Phase II NSCLC of Peregrine Pharmaceuticals
Daiichi-Sankyo = buys out Ambit Biosciences after Peregrine employee Troy Sklenar profile shows working for both Peregrine and Ambit so speculation was that was a collaboration and just a few months later the buyout comes
Sanofi= Sanofi Sunrise initiative taken up... using same name as Peregrine "Sunrise" for their Phase III trial and the docetaxel patent owners at the time
Roche= they begin to lose control
Merck= Merck early ties to Peregrine and later ties to Exelixis http://www.merck.com/licensing/our-partnership/Exelixis-licenses%20PI3K-partnership.html

http://www.exelixis.com/about/strategic-alliances

---------------------------------------------------

now put all or some of the above in perspective and you have Bruce Chabner in the middle and should Peregrine trust him??? Hell No... I think so is that the reason why they may leave him out of the loop....and no communications in 2+ years between Bruce Chabner and Peregrine )

I just find it interesting that Kolltan is all of a sudden making some moves lately this year....

April 13, 2015

Mr. Karbe stated, “I look forward to working with Kolltan’s world-class leadership team, who have demonstrated great success in building oncology companies and delivering novel therapies to patients. I am honored to be given the opportunity to contribute to the advance of promising new therapies that address unmet needs in cancer.”

http://www.businesswire.com/news/home/20150413006108/en/Kolltan-Pharmaceuticals-Appoints-Industry-Veteran-Frank-Karbe#.VgYL2Zf76So

even more and most interesting are the ties to Gilead, beginning back in 2011, though important to remember Joseph Schlessinger is co-founder of Kolltan and as you made note of....re: Kolltan backed out of an IPO and probably given a very good PS Targeting reason to.

---------------------------------------------------------

Yale School of Medicine to get at least $40M from Gilead to find cancer treatments (video)

March 30, 2011

NEW HAVEN -- The Yale School of Medicine will receive a minimum $40 million investment over four years from Gilead Sciences Inc. to discover drug treatments for cancer.

The agreement, which could reach $100 million over 10 years, would give Gilead, based in Foster City, Calif., the first option to develop pharmaceuticals from Yale's discoveries.

"This is a fantastic opportunity for Gilead and for Yale" because the two institutions complement each other, said Dr. Thomas J. Lynch Jr., director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital.

Gilead's strength is in creating therapies to treat diseases, which it has done for HIV and hepatitis, Lynch said. "There's no one better at telling you how to do that," he said.
Advertisement

Where Yale shines is in the basic research to find the molecular basis of cancer.

Professor Joseph Schlessinger, director of the Cancer Biology Institute on Yale University's West Campus, will head a steering committee to choose research targets. The Yale Center for Genome Analysis, led by Professor Richard P. Lifton, will sequence the DNA from tumor cells, an essential part of the process. They will be supported by the "clinical excellence" of Smilow's medical staff, Lynch said.

Read an earlier story about Shlessinger's and Lifkin's cancer research

Schlessinger said Yale will identify the cellular mutations that cause cancer, determine "what will be the effect of this mutation, and then find new ways to block it."

Neither Schlessinger nor Lynch could say how many jobs might be created with the annual infusion of $10 million into the New Haven area economy, but Lynch said "this is a wonderful way to bring jobs, science jobs" to the area. "It's a nice jolt" to the local economy, he said.

Schlessinger has formed three companies to bring cancer treatment discoveries to market: Sugen, later sold to Pfizer, Plexxikon and Kolltan. However, the agreement with Gilead to invest in basic research in the hopes of finding commercially successful pharmaceuticals is rare.

"This is kind of unique because it's a really very close collaboration where we do the research and they do the drug development," Schlessinger said.

Nathan Kaiser, a spokesman for Gilead, said the company is "best known for its work in HIV," having developed Atripla, "the only complete HIV therapy available in one tablet" that comprises three anti-viral drugs.

In a statement, Norbert W. Bischofberger, Gilead's executive vice president for research and development and chief scientific officer, said, "Based on the strong track record of the Yale cancer research team, I am confident this collaboration will lead to important advances in the understanding of the genetic basis of cancer as we collectively seek to develop novel targeted therapies for patients in areas of unmet medical need."

"Yale's faculty in this partnership possess critical and complementary skills that comprise an optimal team for cancer drug development," said Dr. Robert Alpern, dean of the Yale School of Medicine, in a statement. "Tom Lynch brings experience in clinical cancer trials, Rick Lifton has been a leading innovator in genetics and genomics, and Yossi Schlessinger has unparalleled success in cancer drug development."

Yale President Richard C. Levin said, "The collaboration brings together one of the world's top research universities and a biopharmaceutical company dedicated to addressing unmet medical needs with the goal of finding new treatments for cancer.

"This truly is transformative support that leverages the Yale Cancer Center's top scientists, our West Campus technology investments and the resources of the new Smilow Cancer Hospital. I can't think of a better partner to have in this collaboration than Gilead."

http://www.nhregister.com/general-news/20110330/yale-school-of-medicine-to-get-at-least-40m-from-gilead-to-find-cancer-treatments-video